US-based pharmaceutical company Pfizer, together with the German biotechnology giant BioNTech, continues to conduct research on the COVID-19 vaccine, which is a hope for the whole world. While the effects and necessity of the third dose were discussed in the world’s agenda, Pfizer conducted a new research to prove the effect of the third dose.

In this study, in which 10 thousand people aged 16 and over participated, the third dose of vaccine was administered 11 months after the second dose. According to Pfizer’s statements, the average age of this study is 52, and the success rate is 95.6%.

All participants were previously vaccinated with two doses

The research in question included participants who had previously received 2 doses of COVID-19 vaccine. Just as in Pfizer’s previous studies, some of the participants were given doses of placebo and some of the real COVID-19 vaccine.

Stating that one third of the people participating in the study are 65 years old, Pfizer stated that the third dose of vaccine, which is described as a “supplement”, has an effect of 95.6%.